The short answer is no – DMT is illegal in New Mexico as of 2026, classified as a Schedule I controlled substance with severe criminal penalties. While federal law has long prohibited any use, possession, or distribution of N,N‑dimethyltryptamine, the state has reinforced its stance with new amendments that tighten enforcement and expand reporting requirements. Understanding what the law entails, how recent legislative changes affect it, and what exceptions exist is essential for anyone living in or visiting the Land of Enchantment.
Current Legal Status
New Mexico follows the federal Controlled Substances Act, placing DMT on Schedule I. This designation means the drug has a high potential for abuse, no accepted medical use, and lacks safety for use under medical supervision. Possession of any amount is a misdemeanor, while manufacturing or trafficking is a felony. The state’s Criminal Code §30‑22‑1‑19 outlines the penalties, which can range from up to one year in jail for personal possession to 10 years for intent to distribute.
2026 Legislative Changes
In early 2026, the 30th Legislature passed SB 285, amending the existing statutes to:
- Require law‑enforcement agencies to report DMT‑related arrests within 24 hours.
- Increase mandatory minimum sentences for repeat offenders (first felony conviction now carries a 3‑year minimum).
- Expand the definition of “manufacturing” to include the synthesis of DMT precursors such as tryptamine, closing a loophole used by some underground labs.
These changes stem from a rise in reported cases: the New Mexico Department of Public Safety recorded a 27 percent increase in DMT‑related incidents between 2024 and 2025.
Penalties and Enforcement
- Possession (any amount): Class A misdemeanor, up to 12 months imprisonment, $1,000 fine.
- Possession with intent to distribute: Class B felony, minimum 3 years, up to 10 years imprisonment, $25,000 fine.
- Manufacturing or importation: Class A felony, minimum 5 years, up to life imprisonment, $50,000 fine.
Sentencing enhancements apply if the offender is a minor, a law‑enforcement officer, or a repeat offender. Courts often impose mandatory drug‑treatment programs in addition to incarceration.
Medical and Research Exceptions
New Mexico law provides a narrow exemption for research institutions that obtain a Schedule I license from the Drug Enforcement Administration and a state “research permit.” Universities such as the University of New Mexico have secured such permits for neurochemical studies, but the process is rigorous, requiring detailed protocols, secure storage, and annual audits. No therapeutic use is authorized; the state has not adopted the “breakthrough therapy” provisions that some states have recently explored for psychedelic compounds.
What This Means for Residents and Visitors
Anyone found with DMT—whether for personal curiosity, spiritual practice, or trade—faces criminal prosecution under both state and federal law. The 2026 amendments signal stricter enforcement, especially concerning manufacturing and distribution networks. If you are a researcher, ensure all federal and state licensing requirements are satisfied before proceeding. For travelers, be aware that possession in neighboring states does not grant any immunity once you cross into New Mexico.
FAQ
Is DMT classified as a Schedule I drug in New Mexico?
Yes, DMT remains a Schedule I controlled substance, mirroring its federal status.
Can I possess a small amount of DMT for personal use without penalty?
No. Any amount, regardless of intent, is a misdemeanor punishable by up to one year in jail and a fine.
Do the 2026 law changes affect people who already have a research permit?
Existing permits remain valid, but holders must comply with the new reporting and storage requirements introduced by SB 285.
What are the penalties for selling DMT to a minor?
Selling DMT to a minor escalates the charge to a Class A felony with a mandatory minimum of 5 years imprisonment.
Are there any future proposals to de‑schedule DMT in New Mexico?
Legislators have introduced a bill (HB 420) in the 2027 session to create a medical‑research pathway, but it has not yet advanced beyond committee review.